Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 20/20 | 0.61 |
| ▸ | MMP2 | P08253 | 9/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.61 |
| ▸ | MMP14 | P50281 | 2/20 | 0.54 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582781 | 1.00 | ADAMTS5 (0.61) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL20708349 | 0.86 | ADAMTS5 (0.64) | ADAMTS5MMP2ADAM17MMP14 | |
| SCHEMBL21582790 | 0.86 | ADAMTS5 (0.61) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL20708483 | 0.86 | ADAMTS5 (0.61) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL20708471 | 0.86 | ADAMTS5 (0.64) | ADAMTS5MMP2ADAM17MMP14 | |
| SCHEMBL21582750 | 0.84 | ADAMTS5 (0.76) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL20708354 | 0.82 | ADAMTS5 (0.77) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL17871566 | 0.76 | ADAMTS5 (1.00) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL22892302 | 0.76 | ADAMTS5 (0.69) | ADAMTS5MMP2ADAM17MMP14MMP13 | |
| SCHEMBL19709398 | 0.75 | ADAMTS5 (0.68) | ADAMTS5MMP2ADAM17MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |